Trium Capital’s DICE Therapeutics DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-9,600
Closed -$446K – 95
2023
Q2
$446K Buy
+9,600
New +$332K 0.1% 57

Trium Capital's DICE Position: Q3 2023 in Review

Trium Capital sold out of DICE Therapeutics (DICE) in Q3 2023, closing a stake of 39,449 shares — an estimated $1.83M sold.

Trium Capital first reported a position in DICE in Q2 2023 and held it in 1 quarter. The position peaked at $1.83M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Trium Capital reported no remaining DICE Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Trium Capital sold 39,449 DICE Therapeutics shares in Q3 2023, an estimated $1.83M.
  • Trium Capital first reported a position in DICE Therapeutics in Q2 2023 and held it in 1 quarter.
  • Trium Capital's DICE Therapeutics position peaked at $1.83M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics as of Q3 2023.

Based on Trium Capital's 13F filing for Q3 2023, filed 6 Nov 2023.